Online Submissions

Already have a Username/Password for DARU Journal of Pharmaceutical Sciences?
Go to Login

Need a Username/Password?
Go to Registration

Registration and login are required to submit items online and to check the status of current submissions.

Author Guidelines

Instructions to Authors 

Aims and Scope 
The main scope of this journal is to publish articles in different fields of pharmaceutical science from basic to clinic.

 

Types of articles

Original research articles
Novel findings that contribute to advancement of scientific knowledge in pharmaceutical fields will be considered for publication in DARU Journal of Pharmaceutical Sciences (DARU J Pharm Sci) as original research article. These articles should be limited to a maximum of 6000 words or maximum 8 printed pages including a structured abstract of not more than 300 words and 8 figures and tables (combined).

Short communications

New and important information resulting from limited studies but of the same level as original research article will be considered for publication as short communication. These manuscripts should have the same format requirement as full paper but should be limited to maximum 3000 words or maximum 4 printed pages including a structured abstract of not more than 200 words and 4 figures and tables (combined).

Review articles

The results of various investigations in a given area of the pharmaceutical sciences submitted by expertise in the field by invitation of the editors may be considered for publication as review articles. These articles are not required to be divided into different sections but should have an abstract not more than 300 words and introduction sections. At list 10% of references of the review articles should be results of the author investigations published in internationally indexed journals.

Systematic reviews and meta-analyses

These articles should have standards of a systematic review and should be submitted by experts in the field specially by invitation of the editors. These articles are required have standard sections of Introduction, Methods, Results, and Discussion. The abstract should not be more than 300 words. At list 10% of references of the review articles should be results of the author investigations published in internationally indexed journals.

Editorials, expert opinion, and letters to editor

Opinions on professional subjects and the comments to the articles recently published in DARU Journal of Pharmaceutical Sciences (DARU J Pharm Sci) will be considered for publication as editorials, expert opinion, and letters to editor. Editorials should not have subtitles and should be limited to 1500-2000 words including maximum 1 figure or table.

Editorial Policy

All manuscripts will be examined by the Editor-in-Chief and if passed initial requirements, then one of the Associate Editors will be assigned to handle its peer review process. Main initial requirements include novelty of the study and paper, fitting in scope of journal, and full adherence to instruction guideline and ethical principles. DARU Journal of Pharmaceutical Sciences (DARU J Pharm Sci) reserves the right to reject manuscripts that do not fulfill the criteria for submission of the manuscripts.

Submission of Manuscripts

Authors are requested to submit their manuscripts electronically, through http://daru.tums.ac.ir where detailed step by step instruction are stated.
A cover letter written by the corresponding author stating that the manuscript has not been published elsewhere (except in the form of an abstract or as part of a published lecture or academic thesis) and is not concurrently under review for publication elsewhere should accompany the manuscript. In the cover letter the role of each author are recommended to be described according to criteria noted at http://www.icmje.org/ethical_1author.html. If the manuscript is the outcome of a student thesis, it should be noted. For clinical trials, this journal requires registration in a public trials registry. The details of this policy are contained in http://www.icmje.org/publishing_10register.html.

When authors submit a manuscript, they are responsible for disclosing all financial and personal relationships that might bias their work. To prevent ambiguity, authors must state explicitly whether potential conflicts do or do not exist. Authors should note this in body of manuscript at acknowledgment section and also should do so in the cover letter (http://www.icmje.org/ethical_4conflicts.html).

Authors have to consider guidelines and recommendations of ethical points in publication as mentioned by Committee on Publication Ethics (COPE; http://www.publicationethics.org), World Association of Medical Editors (WAME; http://wame.org), International Committee of Medical Journal Editors (http://www.icmje.org/), and European Association of Science Editors (EASE; www.ease.org.uk).

All parts of manuscript including figures and tables should be prepared in single Word file.

 

Preparation of the manuscripts

The manuscript should be typed by Microsoft Office Word program. The font of Times New Roman size 12 and 1.5 line spacing should be used. The abbreviations should be defined as first come; and data should be presented in SI units.
All plant and microorganism's scientific names should be written in italic.
Generic or chemical names of drugs should be used in the text except for studies on comparative effects of different brands. 
The manuscript should be organized as title page, abstract, introduction, methods, results, discussion, conclusion, references, acknowledgments, tables, figures, and illustrations. Authors should state in the manuscript how they have adhered to ethical codes and the code number for approval in institute review board should be stated. The registration code of clinical trials needs to be stated.

Title page
This should include the title, the authors' names, affiliations, addresses, telephone and fax numbers and email address of the corresponding author, place where the work was undertaken and a short title for the running head. Title should be concise in providing information about the content. It should not be capitalized except for the first letter of the first word.

As an obligation, in the title page, the role of each author of the manuscript should be described based on substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; drafting the article or revising it critically for important intellectual content; and final approval of the version to be published.

 

Abstract

The abstract should contain a brief description of the following sections separately:
Background and the purpose of the study, methods, results and major conclusion.

Key words

The abstract should be followed by a maximum of 6 keywords in order of importance pertinent to the subject.

 

Introduction
This section should clearly define the purpose and importance of the research with special attention and suitably references to the background of the study.

 

Methods
This section should provide sufficient information about materials used, their specifications and sources of preparation. The name, model and place of manufacturing of instruments should be stated. Chemical terms should confirm to IUPAC rule. Experimental procedures should provide sufficient information to permit repetition of the work by other workers and /or gives references to the previously published methods.
DARU publishes the results of research involving human subjects only if such research has been conducted in full accordance with ethical principles and a statement describing approval by the Institutional Ethical Committee is required. Studies involving experimental animals must include a statement in the methods section indicating which guidelines were followed for the care and use of the animals. The registration code of clinical trials must be stated.

Results
The important results should be stated with references to tables or figures or schemes. This section should be concise and must not repeat other parts of the manuscript.

Discussion

This section should interpret the results in view of the problems outlined in the introduction and should not repeat the results. The potential of results with appropriate references should be clearly explained.

A clear conclusion which elucidates the general implication of the results should be stated in the last paragraph of this section.

 

Tables and Figures
These are essential to understand the text; the same data should not be presented in both tables and graphs. Abbreviations should be avoided or explained and all data should be identified. Tables or figures should be clearly drawn, headed with a short and descriptive caption and serially numbered in Arabic numerals and provided in separate sheets.

References
Authors are responsible for the accuracy of all references. References should be numbered consecutively as they occur in the text in the parenthesis after last relevant word and listed in numerical order at the end of the text. For more information see the latest issue of the journal.
DARU adheres to the Vancouver style of reference lists (see Uniform Requirements for Manuscripts of the International Committee of Medical Journal Editors, http://www.icmje.org/index.html). Examples are as follow:

Author A, Author B, Author C. Code of publications. DARU J Pharm Sci 2006; 14:102-108.

Author A, Author B, Author C. How to write a paper. In: Author A, ed. Publication in Research. Tehran, TUMS Publishing Co. 2010; 465-478.

 

Acknowledgments

Authors should disclose information on financial conflicts of interest or other interests that may influence the manuscript. Authors may be asked to sign a "conflict of interest" form at the time of submission.

Proofs

Proofs will be sent to the corresponding author for checking. Authors are responsible for all statements in their works including changes made by editor after acceptance of the article.

Copyright Transfer

An agreement of copyright transfer to the publisher (Tehran Medical Sciences University) should be signed and passed as soon as the manuscript is accepted for publication.
There will be no page charge. 
Authors are encouraged to consider the latest issue of DARU J Pharm Sci for the general format of presentation at the following website: http://www.darujps.com

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

1. The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
2. The submission file is in OpenOffice, Microsoft Word, RTF, or WordPerfect document file format.
3. Where available, URLs for the references have been provided.
4. The text is single-spaced; uses a 12-point font; employs italics, rather than underlining (except with URL addresses); and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end.
5. The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines, which is found in About the Journal.
6. If submitting to a peer-reviewed section of the journal, the instructions in Ensuring a Blind Review have been followed.

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.